Journal of Clinical Medicine Article A Comparison of the Clinical and Radiological Extent of Denosumab (Xgeva®) Related Osteonecrosis of the Jaw: A Retrospective Study Zineb Assili 1, Gilles Dolivet 2, Julia Salleron 3 , Claire Griffaton-Tallandier 4, Claire Egloff-Juras 1 and Bérengère Phulpin 1,2,* 1 Faculty of Odontology, Lorraine University, 7 Avenue de la Forêt de Haye, 54505 Vandoeuvre les Nancy, France;
[email protected] (Z.A.);
[email protected] (C.E.-J.) 2 Department of Head and Neck and Dental Surgery, Institut de Cancérologie de Lorraine, 54519 Vadoeuvre-lès-Nancy, France;
[email protected] 3 Cellule Data-Biostatistiques, Institut de Cancérologie de Lorraine, 54519 Vandoeuvre-lès-Nancy, France;
[email protected] 4 Cabinet de Radiologie RX125, 125 Rue Saint-Dizier, 54000 Nancy, France;
[email protected] * Correspondence:
[email protected]; Tel.: +33-3-83-59-84-46 Abstract: Medication-related osteonecrosis of the jaw (MRONJ) is a severe side effect of antiresorptive medication. The aim of this study was to evaluate the incidence of denosumab-related osteonecrosis of the jaw and to compare the clinical and radiological extent of osteonecrosis. A retrospective study of patients who received Xgeva® at the Institut de Cancérologie de Lorraine (ICL) was performed. Patients for whom clinical and radiological (CBCT) data were available were divided into two groups: Citation: Assili, Z.; Dolivet, G.; “exposed” for patients with bone exposure and “fistula” when only a fistula through which the bone Salleron, J.; Griffaton-Tallandier, C.; could be probed was observed. The difference between clinical and radiological extent was assessed.